Search Results

You are looking at 51 - 60 of 372 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

Express Scripts? Really?

Margaret Tempero

Acorda Therapeutics, which is offered to patients free for 2 months before any charges begin. This model makes sense to me. I'm certainly not an expert in commercial enterprise, but I would think a company could shape a business model around this. And I

Full access

Fatigue is the Most Important Symptom for Advanced Cancer Patients Who Have Had Chemotherapy

Zeeshan Butt, Sarah K. Rosenbloom, Amy P. Abernethy, Jennifer L. Beaumont, Diane Paul, Debra Hampton, Paul B. Jacobsen, Karen L. Syrjala, Jamie H. Von Roenn, and David Cella

, Bristol-Myers Squibb, Centocor, Cell Therapeutics, Inc., Genentech, GlaxoSmithKline, Eli Lilly and Company, Merck & Co., Novartis, Ortho Biotech, Pfizer, sanofi-aventis, and Takeda Pharmaceuticals. References 1. Cella DF Tulsky DS Gray G

Full access

Oncology Research Program

metastatic head and neck squamous cell carcinoma (R/M HNSCC) has a dismal survival rate, and development of novel therapeutics has been met with little success. Although immunotherapeutics have shown promise in this devastating disease, most patients do not

Full access

Oncology Research Program

survival, and development of novel therapeutics has been met with little success. Although immunotherapeutics have shown promise in this devastating disease, most patients do not derive a benefit and a sizable population are not candidates for this therapy

Full access

Advocating for Older Adults With Cancer: Merging Medicine and Law

Arti Hurria and Laura A. Levit

highlights of the need for more evidence, 2 , 3 the representation of older adults in NCI trials has not improved, and FDA registration studies still report limited evidence on older adults. 4 – 8 Thus, most of what we know about cancer therapeutics is

Full access

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021

Featured Updates to the NCCN Guidelines

Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Allison Jones, Youn H. Kim, Neha Mehta-Shah, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Sima Rozati, Jonathan Said, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, and Hema Sundar

, Kura Oncology, Inc., Kyowa Hakko Kirin Co., Ltd., ADCT, C4 Therapeutics, Curio, Myeloid Therapeutics, Verastem, Seattle Genetics, Inc., and Takeda Pharmaceuticals North America, Inc.; and that he has received grant/research support from Celgene

Full access

NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022

Featured Updates to the NCCN Guidelines

Elizabeth A. Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird, Rita Cool, Shira Dinner, Mark Geyer, John Glaspy, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Anjlee Mahajan, Ryan Miller, Victoria Nachar, Seema Patel, Shiven Patel, Lia E. Perez, Adam Poust, Fauzia Riaz, Rachel Rosovsky, Hope S. Rugo, Shayna Simon, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Ryan A. Berardi, and Lenora Pluchino

., Ltd., and Takeda Pharmaceuticals North America, Inc.; grant/research support from Astex Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, and Genentech, Inc.; consulting fee from Alexion

Full access

NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022

Featured Updates to the NCCN Guidelines

Margaret von Mehren, John M. Kane III, Richard F. Riedel, Jason K. Sicklick, Seth M. Pollack, Mark Agulnik, Marilyn M. Bui, Janai Carr-Ascher, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Ricardo J. Gonzalez, Ashley Holder, Jade Homsi, Vicki Keedy, Ciara M. Kelly, Edward Kim, David Liebner, Martin McCarter, Sean V. McGarry, Nathan W. Mesko, Christian Meyer, Alberto S. Pappo, Amanda M. Parkes, Ivy A. Petersen, Matthew Poppe, Scott Schuetze, Jacob Shabason, Matthew B. Spraker, Melissa Zimel, Mary Anne Bergman, Hema Sundar, and Lisa E. Hang

Pharmaceuticals, Inc.; and serving as an advisor for Boehringer Ingelheim GmbH, Deciphera Pharmaceuticals, Inc., and GlaxoSmithKline. Seth M. Pollack, MD, Panel Member, has disclosed serving as an advisor for Adaptimmune Therapeutics plc, Deciphera

Full access

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Babis Andreadis, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Julie E. Chang, Beth Christian, Sven DeVos, Bhagirathbhai Dholaria, Luis E. Fayad, Thomas M. Habermann, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Boyu Hu, Mark S. Kaminski, Yasmin Karimi, Christopher R. Kelsey, Rebecca King, Susan Krivacic, Ann S. LaCasce, Megan Lim, Marcus Messmer, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

Products, LP,MEI Pharma Inc.,MorphoSys AG, Novartis Pharmaceuticals Corporation, and Roche Laboratories, Inc.; serving as a scientific advisor for Adaptive Biotechnologies, ADC Therapeutics, Arvinas, and Eli Lilly and Company; and receiving grant

Full access

Clinical Trials in the Age of Pandemics

Martin J. Edelman, Crystal S. Denlinger, Eric A. Ross, and Margaret von Mehren

locally advanced cancer. Even for diseases for which therapeutics have achieved high cure rates, there are trials evaluating strategies to minimize duration and toxicity of treatment. The effort required to formulate, activate, accrue, and analyze trials